Patent safe harbor speeds generic drugs to patients, cuts litigation risk

What it does

This bill creates a legal safe harbor allowing generic drug and biosimilar manufacturers to develop, seek approval for, and market drugs without infringing method-of-use patents—provided their labeling does not claim the patented use. In practice, it lets competitors sell drugs for unapproved uses while the original patent holder's exclusive use claims remain technically valid but unenforceable against the generic/biosimilar version.

Why we flagged it

The bill's operative mechanism is a narrow, conditional immunity from patent infringement liability for competitors who comply with labeling restrictions. It is not a blanket patent repeal but a targeted carve-out for a specific regulatory pathway (ANDA, 505(j), 351(k) applications).

What the text implies

• Patent holders retain legal title and can still sue if a competitor's labeling or promotion references the patented use—the safe harbor is conditional, not absolute, creating ongoing litigation risk over what constitutes a 'reference' to the patented condition.
• The bill applies retroactively to all pending proceedings, potentially reopening settled cases or dismissing ongoing patent suits against generic/biosimilar manufacturers.
• Biosimilar manufacturers gain a safe harbor even if the reference biologic's patent covers a method of use—this may accelerate biosimilar entry into markets where method-of-use patents were previously a barrier.
• The definition of 'promoting' and 'labeling' is cross-referenced to FDA regulations (21 CFR § 202.1, § 314.3), meaning the safe harbor's scope depends on regulatory interpretation and may shift if FDA guidance changes.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Generic and biosimilar drugs reach patients faster and at lower cost when patent litigation risk is reduced. The safe harbor does not eliminate patents—it only shields competitors from suit if they avoid claiming the patented use in their labeling—a transparent, workable boundary that preserves incentives for innovation while accelerating generic/biosimilar entry and competition.

Who stands to gain

• generic pharmaceutical manufacturers
• biosimilar manufacturers
• pharmacy benefit managers and insurers (lower drug costs)
• patients and health plans (reduced drug prices)

Named in the bill

U.S. Patent and Trademark Office, FDA (Food and Drug Administration), Generic drug manufacturers, Biosimilar manufacturers, Pharmaceutical patent holders, 35 U.S.C. § 271, Federal Food, Drug, and Cosmetic Act (sections 505, 512), Public Health Service Act (section 351)

Where it stands

3 cosponsors: 2 Republicans, 1 Democrats.

• Jan 9, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jan 9, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

20 lobbying clients named this bill on 26 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $27,729,577 in lobbying spend. A filing names 23 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 97% of bills with at least one filing.

John Hickenlooper, the sponsor, reported $975,352 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Amgen Inc — $2,440,000 on 1 filing
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Novartis — $1,410,000 on 1 filing
• Apotex Corp. — $990,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.